David Nutt is the Edmond J. Safra Professor of Neuropsychopharmacology at Imperial College London and a globally recognized expert in drug policy and brain pharmacology. He led some of the first neuroimaging studies of psilocybin and LSD, demonstrating the mechanisms of psychedelic action in the human brain. As former Chair of the UK Advisory Council on the Misuse of Drugs, he has been a prominent voice for evidence-based drug policy reform. His CEBM harm ranking of psychoactive substances provided the scientific foundation for reclassifying psilocybin's risk profile.
Nutt's 2010 paper in the Lancet ranking drugs by harm to self and others placed alcohol and tobacco significantly above psilocybin, MDMA, and LSD on evidence-based harm metrics — an analysis that was politically inconvenient but scientifically unassailable. The paper helped reframe public understanding of relative drug risks and provided policymakers with empirical grounding for regulatory reform discussions. His willingness to state that psilocybin is pharmacologically safer than alcohol while remaining a scheduled substance became a touchstone of the evidence-based drug policy movement.
At Imperial College London, Nutt established the neuropsychopharmacology research program that provided the institutional foundation for Carhart-Harris's psilocybin imaging work. His own research contributions include foundational studies on the neuropharmacology of GABA-A receptors, alcohol dependence mechanisms, and the neural basis of psychedelic effects. He was among the first to use fMRI to study psilocybin's effects on brain function in humans.
Beyond the laboratory, Nutt founded Drug Science, an independent scientific committee providing evidence-based drug information free from political influence. His 2012 book Drugs Without the Hot Air and his ongoing public engagement work have reached millions of people with accurate pharmacological information about substances that public discourse typically treats with either demonization or uncritical enthusiasm.